# Clinical trials recruiting in Australia: 2,010 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,010 trials recruiting or not yet recruiting with a site in Australia, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Australia: 2,010 rows for $100.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 40 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/australia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,010
- Recruiting or not yet: 2,010
- Read on: November 19, 2026

## Trials

The 25 newest of 2,010, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946783 | A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Not yet recruiting | Obesity With Cardiovascular Risk Study | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946783) |
| November 18, 2026 | NCT07944690 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944690) |
| November 18, 2026 | NCT07944326 | Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial | University of British Columbia | Phase 3 | Not yet recruiting | Kidney Transplant Recipient | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944326) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 17, 2026 | NCT07941557 | First-in-Human Study of ABS-169 in Healthy Volunteers | Aerys Biosciences | Phase 1 | Not yet recruiting | Healthy Adult Participants, Cardiac Fibrosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941557) |
| November 16, 2026 | NCT07939230 | Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults | Peter MacCallum Cancer Centre, Australia | Phase 1 | Not yet recruiting | HER-2 Positive Advanced Solid Tumors, HER-2 Positive Breast Cancer, HER-2 Positive Advanced Gastric Cancer, HER-2... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939230) |
| November 16, 2026 | NCT07938814 | A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938814) |
| November 13, 2026 | NCT07935941 | A Phase I Study of HLX109 in Healthy Participants | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | First in Man Study to Evaluate Initial Safety | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935941) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 10, 2026 | NCT07928388 | Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency | Medicure | Phase 3 | Recruiting | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928388) |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926334) |
| November 6, 2026 | NCT07923097 | Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable. | Rapport Therapeutics Inc. | Phase 1 | Recruiting | Epilepsy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923097) |
| November 6, 2026 | NCT07921576 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia | Dartsbio Pharmaceuticals Ltd. | Phase 1/2 | Recruiting | Cancer, Cachexia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921576) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 5, 2026 | NCT07917780 | A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With... | German CLL Study Group | Phase 2 | Recruiting | Richter Transformation | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917780) |
| November 4, 2026 | NCT07916857 | Comparison of VxWave and Standard Ultrasound Measurements of Blood Vessels in the Arm | Vexev Pty Ltd | Not applicable | Not yet recruiting | Upper Limb Vascular Imaging | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916857) |
| November 4, 2026 | NCT07916727 | Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO Study | Austin Health | Not applicable | Recruiting | Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Pregnancy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916727) |
| November 4, 2026 | NCT07915375 | Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue | Murdoch Childrens Research Institute | Observational | Not yet recruiting | Fertility, Testicular Tissue Cryopreserved, Fertility Preservation | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915375) |
| November 4, 2026 | NCT07915297 | Safety and Biodistribution of \[68Ga\]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) | Luminance Biosciences Inc | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915297) |
| November 3, 2026 | NCT07913594 | Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma Refractory | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913594) |
| October 30, 2026 | NCT07908147 | Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | IDH Wildtype Glioblastoma, Glioblastoma (GBM) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908147) |
| October 29, 2026 | NCT07905053 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants | Cibus Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Pancreatitis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905053) |
| October 29, 2026 | NCT07904689 | A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis | North Immunology Inc. | Phase 1 | Not yet recruiting | Atopic Dermatitis (AD) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904689) |
| October 29, 2026 | NCT07903779 | Effects of Smartphone Use and Television Viewing on Standardized BP Measurement: The SCREENS-BP Study | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Not applicable | Not yet recruiting | Hypertension | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903779) |
| October 29, 2026 | NCT07903493 | Phase Ia Study of MST-931 in Healthy Adult Subjects | Mabsoft Therapeutics (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Ankylosing Spondylitis (AS) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903493) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Westmead Hospital | Westmead | 156 |
| Princess Alexandra Hospital | Woolloongabba | 127 |
| Peter MacCallum Cancer Centre | Melbourne | 123 |
| Royal Adelaide Hospital | Adelaide | 114 |
| The Alfred Hospital | Melbourne | 106 |
| Royal Prince Alfred Hospital | Camperdown | 93 |
| Austin Health | Heidelberg | 92 |
| Monash Health | Clayton | 84 |
| Royal North Shore Hospital | St Leonards | 83 |
| Fiona Stanley Hospital | Murdoch | 78 |
| Flinders Medical Centre | Bedford Park | 75 |
| Perth Children's Hospital | Nedlands | 72 |
| Royal Melbourne Hospital | Melbourne | 67 |
| Royal Brisbane and Women's Hospital | Herston | 65 |
| Sir Charles Gairdner Hospital | Nedlands | 61 |
| Linear Clinical Research | Murdoch | 60 |
| Liverpool Hospital | Liverpool | 59 |
| Queensland Children's Hospital | Brisbane | 52 |
| Macquarie University | Sydney | 50 |
| Monash Medical Centre | Clayton | 50 |
| John Hunter Hospital | New Lambton Heights | 49 |
| Gold Coast University Hospital | Southport | 49 |
| Box Hill Hospital | Box Hill | 48 |
| Concord Repatriation General Hospital | Concord | 48 |
| Royal Perth Hospital | Perth | 46 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 15 |
| Phase 1 | 382 |
| Phase 1/2 | 258 |
| Phase 2 | 287 |
| Phase 2/3 | 73 |
| Phase 3 | 496 |
| Phase 4 | 45 |
| Not applicable | 246 |
| Observational | 208 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 116 |
| Neoplasms | 79 |
| Breast Neoplasms | 77 |
| Neoplasm Metastasis | 57 |
| Colorectal Neoplasms | 55 |
| Prostatic Neoplasms | 54 |
| Obesity | 52 |
| Lung Neoplasms | 47 |
| Recurrence | 44 |
| Ovarian Neoplasms | 44 |
| Melanoma | 42 |
| Multiple Myeloma | 42 |
| Overweight | 35 |
| Endometrial Neoplasms | 35 |
| Squamous Cell Carcinoma of Head and Neck | 31 |
| Lymphoma, Non-Hodgkin | 29 |
| Triple Negative Breast Neoplasms | 28 |
| Pancreatic Neoplasms | 28 |
| Small Cell Lung Carcinoma | 26 |
| Stomach Neoplasms | 26 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 23 |
| Lymphoma | 23 |
| Diabetes Mellitus, Type 2 | 22 |
| Cardiovascular Diseases | 22 |
| Carcinoma, Hepatocellular | 22 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 82 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 54 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 34 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 34 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 33 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 31 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 30 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 30 |
| Murdoch Childrens Research Institute | 29 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 29 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 26 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 24 |
| University of Sydney | 23 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 23 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 22 |
| Monash University | 19 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 18 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 18 |
| Peter MacCallum Cancer Centre, Australia | 18 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 18 |
| University of Melbourne | 17 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 16 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 14 |
| Children's Oncology Group | 13 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 12 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
- [Grout companies in the United States](https://specstream.ai/data/businesses/grout-companies/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
